ClinicalTrials.gg
CompletedNCT01726335Updated Apr 29, 2014Results posted

Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia

A Phase 4 interventional study of Risperidone prolonged release in Schizophrenia, sponsored by Janssen-Cilag Ltd.. Completed at 5 sites in Brazil. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-04-29.

Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Schizophrenia by Johnson & Johnson — 2 open to participants now, 2 under way, 1 of them phase 3. Schizophrenia · Johnson & Johnson.

Enrollment
130th of 176
53 · median 165
Started
2006
with 15 others
Phase 4
47 of 206
none open now
Registered
173rd of 206
by date

Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 130th largest by enrollment of the 176 interventional ones that give a count, is one of 16 that started in 2006, is one of 47 in phase 4, and was the 173rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 206 studies in Schizophrenia by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Schizophrenia by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy, safety and tolerance of long-acting risperidone when switching from oral antipsychotics in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Read the detailed description

This is an open-label (all people know the identity of the intervention), multi-centric (conducted in more than one center) and non-comparative study of long-acting risperidone in participants with schizophrenia who have a previous history (in the last 12 months) of bad adherence to the oral antipsychotic treatment of first or second generation. The duration of this study will be 24 weeks and will include following visits: Screening, Baseline, Week 2, 4, 8, 12, 16, 20, 24, 38 and 50 (End visit or early withdrawal). All the eligible participants (after risperidone intolerance test during screening) will receive a dose of 25 milligram risperidone every two weeks by intramuscular injection (injection of a substance into a muscle). Efficacy and safety of the participants will primarily be evaluated by Positive and Negative Syndromes Scale and Extrapyramidal Symptom Rating Scale, respectively. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Risperidone
  • Risperdal consta
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have schizophrenia diagnosis by , fourth edition (DSM-IV)
  • Be on treatment with oral antipsychotic of first or second generation, for a minimum time of 12 months
  • Previous history of bad adhesion to oral antipsychotic treatment in the last 12 months
  • Total Positive and Negative Syndrome Scale score less than or equal to 90, the conceptual disorganization, hallucinatory behavior, suspicion and not usual content of thought must be less than or equal to 4
  • Be not pregnant as showed on negative pregnancy serum test

Exclusion criteria

Exclusion Criteria:

  • or known to risperidone
  • Previous history of unsatisfactory response to risperidone
  • Previous history of refractivity to the other second generation antipsychotics
  • Use of antipsychotic of intramuscular deposit in the last 12 months
  • Other mental disturbances of axis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Risperidone prolonged release

    Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.

    Drug: Risperidone prolonged release

Interventions

  • DrugRisperidone prolonged release

    Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.

    Also known as: - Risperdal consta

06

What researchers measure

Primary outcomes

  1. Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 2

  2. Positive and Negative Syndromes Scale (PANSS) Total Score at Week 4

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 4

  3. Positive and Negative Syndromes Scale (PANSS) Total Score at Week 8

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 8

  4. Positive and Negative Syndromes Scale (PANSS) Total Score at Week 16

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 16

  5. Positive and Negative Syndromes Scale (PANSS) Total Score at Week 24

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 24

  6. Positive and Negative Syndromes Scale (PANSS) Total Score at Week 38

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 38

  7. Positive and Negative Syndromes Scale (PANSS) Total Score at Week 50

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 50

Secondary outcomes

  1. Clinical Global Impressions (CGI) - Disease Severity Score

    The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to "normal, not at all ill" and a rating of 7 indicates "among the most extremely ill participants". Higher scores indicate worsening.

    Time frame: Baseline and Week 2, 4, 8, 16, 24, 38 and 50

  2. Extrapyramidal Symptoms Rating Scale (ESRS) Total Score

    The ESRS is used to assess four types of drug-induced movement disorders administered as a questionnaire. Score range from 0 to 6 (0 is absent and 6 is extremely severe).

    Time frame: Baseline and Week 2, 4, 8, 16, 24 and 50

  3. Drug Attitude Inventory (DAI-10)

    The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant). The final score is the grand total of the positive and negative points. Total score ranges from (-) 10 to (+) 10, higher score indicates positive SR (compliant) and lower score indicates negative SR (non-compliant).

    Time frame: Screening, and Week 8, 24 and 50

  4. Short Form-36 (SF-36) - Quality of Life

    The SF-36 is a survey of participant health. It consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state.

    Time frame: Baseline and Week 50

  5. Personal and Social Performance (PSP) Scale Score

    The PSP scale assesses the degree of a participant's dysfunction (ranging from i \[absent\] to vi \[very severe) within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behavior. The overall score ranges from 1 to 100. Based on the 4-domains there was one total score. Participants with a score of 71 to 100 had a mild degree of difficulty; from 31 to 70, varying degrees of disability; participants with scores of 30 or less function so poorly as to require intensive supervision.

    Time frame: Screening, and Week 8, 16, 24, 38 and 50

  6. Global Assessment of Functioning (GAF) Scale Score

    The GAF scale is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.

    Time frame: Screening, and Week 8, 16, 24, 38 and 50

07

Results

Posted Jul 24, 2013

Participant flow

Participant flow — Overall Study
MilestoneRisperidone Prolonged Release
Started53
Completed29
Not completed24
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject15
Withdrew: Adverse event4
Withdrew: Lost to follow-up2
Withdrew: Exacerbation of psychotic symptoms1

Outcome measures

PrimaryPositive and Negative Syndromes Scale (PANSS) Total Score at Week 2

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 2
Reported as:
Mean · Units on a scale
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2
Units on a scaleRisperidone Prolonged Release
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 255.53 ± 1.82
PrimaryPositive and Negative Syndromes Scale (PANSS) Total Score at Week 4

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 4
Reported as:
Mean · Units on a scale
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 4
Units on a scaleRisperidone Prolonged Release
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 453.82 ± 1.83
PrimaryPositive and Negative Syndromes Scale (PANSS) Total Score at Week 8

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 8
Units on a scaleRisperidone Prolonged Release
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 851.28 ± 1.86
PrimaryPositive and Negative Syndromes Scale (PANSS) Total Score at Week 16

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 16
Reported as:
Mean · Units on a scale
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 16
Units on a scaleRisperidone Prolonged Release
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 1650.55 ± 1.98
PrimaryPositive and Negative Syndromes Scale (PANSS) Total Score at Week 24

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 24
Reported as:
Mean · Units on a scale
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 24
Units on a scaleRisperidone Prolonged Release
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2448.95 ± 2.13
SecondaryClinical Global Impressions (CGI) - Disease Severity Score

The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to "normal, not at all ill" and a rating of 7 indicates "among the most extremely ill participants". Higher scores indicate worsening.

Time frame:
Baseline and Week 2, 4, 8, 16, 24, 38 and 50
Reported as:
Mean · Units on a scale
Clinical Global Impressions (CGI) - Disease Severity Score
Units on a scaleRisperidone Prolonged Release
Baseline3.55 ± 0.13
Week 23.37 ± 0.13
Week 43.30 ± 0.13
Week 83.21 ± 0.13
Week 163.10 ± 0.14
Week 242.92 ± 0.15
Week 382.94 ± 0.15
Week 503.19 ± 0.16
SecondaryExtrapyramidal Symptoms Rating Scale (ESRS) Total Score

The ESRS is used to assess four types of drug-induced movement disorders administered as a questionnaire. Score range from 0 to 6 (0 is absent and 6 is extremely severe).

Time frame:
Baseline and Week 2, 4, 8, 16, 24 and 50
Reported as:
Mean · Units on a scale
Extrapyramidal Symptoms Rating Scale (ESRS) Total Score
Units on a scaleRisperidone Prolonged Release
Baseline0.460 ± 0.073
Week 20.416 ± 0.072
Week 40.272 ± 0.073
Week 80.289 ± 0.074
Week 160.271 ± 0.079
Week 240.221 ± 0.082
Week 500.089 ± 0.086
SecondaryDrug Attitude Inventory (DAI-10)

The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant). The final score is the grand total of the positive and negative points. Total score ranges from (-) 10 to (+) 10, higher score indicates positive SR (compliant) and lower score indicates negative SR (non-compliant).

Time frame:
Screening, and Week 8, 24 and 50
Reported as:
Mean · Units on a scale
Drug Attitude Inventory (DAI-10)
Units on a scaleRisperidone Prolonged Release
Screening2.78 ± 0.62
Week 84.45 ± 0.64
Week 244.59 ± 0.69
Week 505.07 ± 0.77
SecondaryShort Form-36 (SF-36) - Quality of Life

The SF-36 is a survey of participant health. It consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state.

Time frame:
Baseline and Week 50
Reported as:
Mean · Units on a scale
Short Form-36 (SF-36) - Quality of Life
Units on a scaleRisperidone Prolonged Release
Functional capacity : Baseline79.2 ± 21.4
Physical aspect : Baseline48.2 ± 40.2
Pain : Baseline73.7 ± 27.2
Health General State : Baseline60.7 ± 18.4
Vitality : Baseline53.8 ± 21.2
Social Aspect : Baseline56.1 ± 28.0
Emotional Aspect : Baseline34.9 ± 38.4
Mental Health : Baseline58.9 ± 21.9
Functional capacity : Week 5067.9 ± 31.6
Physical aspect : Week 5052.9 ± 41.3
Pain : Week 5075.4 ± 29.5
Health General State : Week 5062.7 ± 19.5
Vitality : Week 5053.1 ± 18.3
Social Aspect : Week 5059.9 ± 26.2
Emotional Aspect : Week 5055.0 ± 41.7
Mental Health : Week 5056.6 ± 20.6
PrimaryPositive and Negative Syndromes Scale (PANSS) Total Score at Week 38

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 38
Reported as:
Mean · Units on a scale
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 38
Units on a scaleRisperidone Prolonged Release
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 3847.40 ± 2.26
PrimaryPositive and Negative Syndromes Scale (PANSS) Total Score at Week 50

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 50
Reported as:
Mean · Units on a scale
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 50
Units on a scaleRisperidone Prolonged Release
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 5049.72 ± 2.32
SecondaryPersonal and Social Performance (PSP) Scale Score

The PSP scale assesses the degree of a participant's dysfunction (ranging from i \[absent\] to vi \[very severe) within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behavior. The overall score ranges from 1 to 100. Based on the 4-domains there was one total score. Participants with a score of 71 to 100 had a mild degree of difficulty; from 31 to 70, varying degrees of disability; participants with scores of 30 or less function so poorly as to require intensive supervision.

Time frame:
Screening, and Week 8, 16, 24, 38 and 50
Reported as:
Mean · Units on a scale
Personal and Social Performance (PSP) Scale Score
Units on a scaleRisperidone Prolonged Release
Screening60.0 ± 2.9
Week 866.4 ± 2.4
Week 1672.6 ± 2.3
Week 2471.7 ± 2.1
Week 3871.8 ± 2.1
Week 5069.1 ± 2.2
SecondaryGlobal Assessment of Functioning (GAF) Scale Score

The GAF scale is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.

Time frame:
Screening, and Week 8, 16, 24, 38 and 50
Reported as:
Mean · Units on a scale
Global Assessment of Functioning (GAF) Scale Score
Units on a scaleRisperidone Prolonged Release
Screening62.6 ± 3.1
Week 867.5 ± 2.6
Week 1672.5 ± 2.5
Week 2471.4 ± 2.3
Week 3873.9 ± 2.3
Week 5068.6 ± 2.3

Adverse events

Collected over Baseline up to Week 50. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risperidone Prolonged Release—3/53 (5.7%)40/53 (75.5%)
Most frequent serious events
Most frequent serious events
EventRisperidone Prolonged Release
Psychomotor hyperactivityNervous system disorders1/53
Psychotic disorderPsychiatric disorders1/53
SchizophreniaPsychiatric disorders1/53
Most frequent other events
Showing 10 of 51
Most frequent other events
EventRisperidone Prolonged Release
Libido decreasedPsychiatric disorders12/53
Weight increasedInvestigations7/53
Blood prolactin increasedInvestigations6/53
AnxietyPsychiatric disorders4/53
Schizophrenia, disorganised typePsychiatric disorders4/53
HyperprolactinaemiaEndocrine disorders3/53
Abdominal pain upperGastrointestinal disorders3/53
Decreased appetiteMetabolism and nutrition disorders3/53
Musculoskeletal painMusculoskeletal and connective tissue disorders3/53
SchizophreniaPsychiatric disorders3/53

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Risperidone Prolonged Release
Mean33.6 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Risperidone Prolonged Release
Female14
Male39
Positive and Negative Syndromes Scale (PANSS) Total Score
Positive and Negative Syndromes Scale (PANSS) Total Score(Units on a scale)Risperidone Prolonged Release
Mean58.80 ± 1.82
08

Study locations

5 sites
  • Curitiba, Brazil
  • Porto Alegre, Brazil
  • Rio De Janeiro, Brazil
  • Salvador, Brazil
  • Sao Paulo, Brazil
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2012
First posted
Nov 14, 2012
Start
Jan 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Jul 24, 2013
Last update
Apr 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01726335
Lead sponsor
Janssen-Cilag Ltd.
Responsible party
Sponsor
First posted
Nov 14, 2012
Start date
Jan 2006
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Jul 24, 2013
Last update
Apr 29, 2014

Study contacts

Janssen-Cilag Ltd. Clinical trial
study director · Janssen-Cilag Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion